Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bafna Pharmaceuticals, an India-based pharmaceutical company, said that its Chennai manufacturing plant has got the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to manufacture clonazepam 0.5mg and 2mg tablets, to treat anxiety, to be sold in the UK.
Subscribe to our email newsletter
Bafna said that Clonazepam, for oral administration, falls under a group of drugs called benzodiazepines. Clonazepam is used to control certain types of seizures in the treatment of epilepsy and for the treatment of panic disorders.
Clonazepam tablets also contain lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, purified water, and corn starch.
Bafna Pharma said that with this latest approval in total the company has received 9 formulation approvals from MHRA for contract manufacturing.
Mahaveer Chand Bafna, chairman and MD of Bafna Pharma, said: “The approval from UK MHRA will provide further momentum to our already expanding business in the European market. UK MHRA approval will enable Bafna Pharma to widen the customer base in Europe.
“Following the recent launch of our FR&D facility in Chennai, we will be filing dossiers for the ever growing UK and the European Markets.”